Journey Medical Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DERM research report →
Companyjourneymedicalcorp.com
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution.
- CEO
- Claude Maraoui
- IPO
- 2021
- Employees
- 41
- HQ
- Scottsdale, AZ, US
Price Chart
Valuation
- Market Cap
- $169.81M
- P/E
- -17.57
- P/S
- 2.63
- P/B
- 5.46
- EV/EBITDA
- -93.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.41%
- Op Margin
- -9.80%
- Net Margin
- -14.82%
- ROE
- -35.57%
- ROIC
- -11.26%
Growth & Income
- Revenue
- $61.86M · 10.20%
- Net Income
- $-11,431,000 · 22.09%
- EPS
- $-0.47 · 34.72%
- Op Income
- $-8,172,000
- FCF YoY
- -36.31%
Performance & Tape
- 52W High
- $9.55
- 52W Low
- $4.31
- 50D MA
- $5.65
- 200D MA
- $7.25
- Beta
- 1.03
- Avg Volume
- 255.94K
Get TickerSpark's AI analysis on DERM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 26 | Alloush Ramsey | other | 46,863 |
| Apr 22, 26 | Alloush Ramsey | other | 62,795 |
| Apr 22, 26 | Benesch Joseph | other | 28,907 |
| Apr 22, 26 | Benesch Joseph | other | 41,860 |
| Apr 22, 26 | Maraoui Claude | other | 49,277 |
| Apr 22, 26 | Maraoui Claude | other | 82,915 |
| Aug 25, 25 | Maraoui Claude | other | 1,250,000 |
| Aug 25, 25 | Maraoui Claude | other | 10,877 |
| Aug 25, 25 | Maraoui Claude | other | 1,250,000 |
| Aug 5, 25 | ROSENWALD LINDSAY A MD | other | 50,000 |
Our DERM Coverage
We haven't published any research on DERM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DERM Report →